Sanofi has entered into an agreement to develop 15 experimental oncology and immunological drugs with Exscientia, a company that uses artificial intelligence to produce new drugs. Possible total payments reach $ 5.2 billion, according to Bloomberg
The company based in Oxford, England will receive $ 100 million in advance, as well as before and rights from successful treatments, the companies announced on Friday.
This is the latest effort by Sanofi CEO Paul Hudson to revitalize the development of the French pharmaceutical industry. Last month, Sanofi agreed to buy private Amunix Pharmaceuticals for $ 1.2 billion for its promising cancer drugs. Sanofi also bought mRNA development company Translate Bio last year for $ 3.2 billion and US biotechnology company Kadmon Holdings Inc. against $ 1.9 billion.
Sanofi has been working with Exscientia since 2016. In 2019, Sanofi obtained a license for a candidate drug from the company that aims to fight inflammation.
The collaboration aims to transform the way new small-molecule drugs are developed for cancer and immunodeficiency diseases, said Frank Nestle, Sanofi’s global head of research and scientific director.
Exscientia was founded in 2012 and considers itself a “pharmatech” (pharmaceutical-technological) company that uses artificial intelligence to accelerate the development of small molecule drugs. Such drugs, often known as targeted therapies, can interfere with specific molecules inside cells and thus prevent the growth and spread of cancer.
Exscientia has more than 25 projects in progress, including three candidate drugs designed by artificial intelligence (AI) for cancer and psychiatry that are already in early clinical trials, the company said. The company tests its candidate drugs on human tissue samples in preclinical tests rather than conventional methods, which often involve mice.
Exscientia made its initial public offering of ADS last year and today has a market value of $ 2.1 billion, according to data compiled by Bloomberg.
.
Source From: Capital
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
